NAMPT and steatosis: Other studies suggest that manipulation of NAMPT renders the liver more susceptible toward hepatic lipid accumulation, as both treatment with the NAMPT inhibitor FK866 and overexpression of a dominant-negative Nampt mutation induces susceptibility to steatosis development (6, 18).